A(s) Individualização do tratamento com topiramato em pacientes infantis com epilepsia focal
Article Sidebar
Main Article Content
Abstract
Topiramate is an antiepileptic medication used in partial epilepsy seizures in adults and children, acting on the central nervous system (CNS) and bringing balance to neurological cells. The study is applicable to pediatric patients, where the beneficial effects of individualization are demonstrated, mainly because it is a weak enzyme inducer, as will be explained throughout this article. The manuscript aims to demonstrate the behavior of the drug topiramate when administered individually to children, taking into account pharmacogenetics that aims to understand the genetic variability of each individual with regard to specific medications, in addition to a succinct comparison with older antiepileptic drugs (AEDs) that are still used as first-line medications in the treatment of childhood partial epilepsy. The study was based on research carried out on the platforms: Google Scholar, PubMed and Scielo. In the search, words in English that correlated with the proposed theme were used and the selected articles had as selection criteria the number of times they were cited and the year of publication. After the searches, 32 articles were selected that formed the study in question, including articles related to partial childhood epilepsy, topiramate and pharmacogenetics. In short, it is understood that studies based on pharmacogenetics will be more widespread over the years, so that there can be increasingly personalized and individualized treatments for patients with epilepsy, especially among children.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Statement - Policy Proposal for Open Access Journals
Authors who publish in The Brazilian journal of Biomedical Sciences (RBCBM) agree to the following terms: 1 - Authors retain the copyright and grant the journal the right to first publication, with the work simultaneously licensed under the Creative Commons Attribution License allowing sharing of the work with recognition of the authorship of the work and initial publication in this journal. 2 - Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. 3 - Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and citation of published work.
This is an open access article under the CC-BY license
(http://creativecommons.org/licenses/by/4.0)
References
Costa LL de O, Bran dão EC, Segundo LM de BM. Atualização em epilepsia: revisão de literatura. Revista de Medicina [Internet]. 2020 Apr 24;99(2):170–81.
Focal and Non-Focal Epilepsy Localization: A Review [Internet]. ieeexplore.ieee.org.
Lyseng-Williamson KA, Yang LPH. Topiramate. Drugs. 2007;67(15):2231–56.
Rocha C, Brucki SMD. Topiramato: uma experiência em crianças com epilepsia parcial. Arquivos de Neuro-Psiquiatria. 2001 Sep;59(3B):768–71.
Lyseng-Williamson KA, Yang LPH. Topiramate. Drugs. 2007;67(15):2231–56.
Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neuroscience Letters. 2018 Feb;667:27–39.
Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nature Reviews Genetics [Internet]. 2003 Dec 1;4(12):937–47.
Burman RJ, Parrish RR. The Widespread Network Effects of Focal Epilepsy. The Journal of Neuroscience. 2018 Sep 19;38(38):8107–9.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia [Internet]. 2014 Apr;55(4):475–82.
Combs SE, Pearl PL. Classification and Definition of Seizures and Epilepsy Syndromes in Childhood. Epilepsy in Children and Adolescents. 2012 Nov;17–36.
Shank RP, Maryanoff BE. Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate. CNS Neuroscience & Therapeutics. 2008 Jun;14(2):120–42.
Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics [Internet]. 2004;43(12):763–80.
Girgis IG, Nandy P, Nye JS, Ford L, Mohanty S, Wang S, et al. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age. Epilepsia. 2010 Sep 29;51(10):1954–62.
Johannessen SI, Tomson T. Pharmacokinetic Variability of Newer Antiepileptic Drugs. Clinical Pharmacokinetics. 2006;45(11):1061–75.
Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clinical Pharmacokinetics. 2013 Jun 22;52(12):1045–61.
Ahmed GF, Marino SE, Brundage RC, Serguei Pakhomov, Leppik IE, Cloyd JC, et al. Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. British Journal of Clinical Pharmacology. 2015 Apr 22;79(5):820–30.
Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. 2006 Mar 24;7(6):811–23.
Latini G, Verrotti A, Manco R, Scardapane A, Vecchio A, Chiarelli F. Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy. Mini-Reviews in Medicinal Chemistry. 2008 Jan 1;8(1):10–23.
Costa LL de O, Brandão EC, Segundo LM de BM. Atualização em epilepsia: revisão de literatura. Revista de Medicina [Internet]. 2020 Apr 24;99(2):170–81.
Guerrini R. Epilepsy in children. The Lancet [Internet]. 2006 Feb 11 [cited 2021 Feb 17;367(9509):499–524.
Singh R, McKinlay Gardner R J., Crossland Kathryn M, Scheffer Ingrid E, Berkovic Samuel F. Chromosomal Abnormalities and Epilepsy: A Review for Clinicians and Gene Hunters. Epilepsia. 2002 Mar 19;43(2):127–40.
Zarezadeh M, Khorshidi M, Emami M, Janmohammadi P, Kord-varkaneh H, Mousavi SM, et al. Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. European Journal of Nutrition [Internet]. 2020 Aug 1 [cited 2021 Apr 18];59(5):1803.
Guttman Y, Nudel A, Kerem Z. Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related. Frontiers in Genetics. 2019 Mar 19;10.
Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics [Internet]. 2007 Sep 1 [cited 2023 Oct 19];8(9):1151–8.
Wang Q. ABCB1 Gene C3435T Polymorphism and Drug Resistance in Epilepsy: Evidence Based on 8604 Subjects. Medical Science Monitor. 2015;21:861–8.
Smolarz B, Makowska M, Romanowicz H. Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature). International Journal of Molecular Sciences. 2021 Oct 28;22(21):11696.
Li Z, Cao W, Sun H, Wang X, Li S, Ran X, et al. Potential clinical and biochemical markers for the prediction of drug-resistant epilepsy: A literature review. Neurobiology of Disease [Internet]. 2022 Nov 1;174:105872.
Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 2013 May 3;54(7):1270–81.
Moseley BD, Dhamija R, Wirrell EC, Nickels KC. Historic, Clinical, and Prognostic Features of Epileptic Encephalopathies Caused by CDKL5 Mutations. Pediatric Neurology. 2012 Feb;46(2):101–5.
Moosa ANV. Antiepileptic Drug Treatment of Epilepsy in Children. CONTINUUM: Lifelong Learning in Neurology. 2019 Apr;25(2):381–407.
Voronkova KV, Pyleva OA, Petrukhin AS. [Efficacy of topiramate (topamax) in epileptic patients of different age]. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova [Internet]. 2006;106(6):34–7.
Szoeke CEI, Newton M, Wood JM, Goldstein D, Berkovic SF, OBrien TJ, et al. Update on pharmacogenetics in epilepsy: a brief review. The Lancet Neurology [Internet]. 2006 Feb 1 [cited 2020 Feb 28];5(2):189–96.